Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia-Pacific. More Details
Acceptable track record with limited growth.
Share Price & News
How has Chr. Hansen Holding's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHR has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CHR exceeded the Danish Chemicals industry which returned 9.8% over the past year.
Return vs Market: CHR underperformed the Danish Market which returned 35.6% over the past year.
Price Volatility Vs. Market
How volatile is Chr. Hansen Holding's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StTime To Worry? Analysts Are Downgrading Their Chr. Hansen Holding A/S (CPH:CHR) Outlook
2 weeks ago | Simply Wall StHere's Why Chr. Hansen Holding (CPH:CHR) Can Manage Its Debt Responsibly
1 month ago | Simply Wall StShould You Be Excited About Chr. Hansen Holding A/S' (CPH:CHR) 30% Return On Equity?
Is Chr. Hansen Holding undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CHR (DKK664.2) is trading above our estimate of fair value (DKK238.54)
Significantly Below Fair Value: CHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CHR is poor value based on its PE Ratio (50.8x) compared to the XE Chemicals industry average (21.6x).
PE vs Market: CHR is poor value based on its PE Ratio (50.8x) compared to the Danish market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: CHR's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: CHR is overvalued based on its PB Ratio (13.2x) compared to the XE Chemicals industry average (1.6x).
How is Chr. Hansen Holding forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHR's earnings are forecast to decline over the next 3 years (-1.1% per year).
Earnings vs Market: CHR's earnings are forecast to decline over the next 3 years (-1.1% per year).
High Growth Earnings: CHR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: CHR's revenue (8.9% per year) is forecast to grow faster than the Danish market (6.3% per year).
High Growth Revenue: CHR's revenue (8.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CHR's Return on Equity is forecast to be high in 3 years time (21.3%)
How has Chr. Hansen Holding performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHR has high quality earnings.
Growing Profit Margin: CHR's current net profit margins (23.9%) are lower than last year (24.4%).
Past Earnings Growth Analysis
Earnings Trend: CHR's earnings have grown by 7.9% per year over the past 5 years.
Accelerating Growth: CHR's earnings growth over the past year (1%) is below its 5-year average (7.9% per year).
Earnings vs Industry: CHR earnings growth over the past year (1%) exceeded the Chemicals industry -10.9%.
Return on Equity
High ROE: Whilst CHR's Return on Equity (25.94%) is high, this metric is skewed due to their high level of debt.
How is Chr. Hansen Holding's financial position?
Financial Position Analysis
Short Term Liabilities: CHR's short term assets (€607.1M) do not cover its short term liabilities (€1.0B).
Long Term Liabilities: CHR's short term assets (€607.1M) do not cover its long term liabilities (€943.3M).
Debt to Equity History and Analysis
Debt Level: CHR's debt to equity ratio (147.7%) is considered high.
Reducing Debt: CHR's debt to equity ratio has increased from 94% to 147.7% over the past 5 years.
Debt Coverage: CHR's debt is well covered by operating cash flow (27.6%).
Interest Coverage: CHR earns more interest than it pays, so coverage of interest payments is not a concern.
What is Chr. Hansen Holding current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CHR is not paying a notable dividend for the Danish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHR's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mauricio Graber (57 yo)
Mr. Mauricio Graber has been Chief Executive Officer, President and Member of Executive Board of Chr. Hansen Holding A/S since joining it on June 1, 2018. Mr. Graber serves as Director of Jungbunzlauer Sui ...
CEO Compensation Analysis
Compensation vs Market: Mauricio's total compensation ($USD3.65M) is about average for companies of similar size in the Danish market ($USD3.27M).
Compensation vs Earnings: Mauricio's compensation has been consistent with company performance over the past year.
|CEO, President & Member of Executive Board||2.33yrs||€3.10m||0.017% |
|Executive VP & Member of Executive Board||5.17yrs||€966.00k||0.0031% |
|Executive VP||2.92yrs||€636.00k||0.0018% |
|CFO & Member of Executive Board||no data||no data||no data|
|Executive Vice President of Global Operations||3.75yrs||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Corporate Vice President of Compliance & Corporate Affairs||4.33yrs||no data||no data|
|Head of Media Relations||no data||no data||no data|
|Corporate Vice President of Global Human Resources||4.25yrs||no data||no data|
|VP & Head of Food||no data||no data||no data|
|Executive Vice President of Food Cultures & Enzymes||4.08yrs||no data||no data|
|Executive Vice President of Health & Nutrition||no data||no data||no data|
Experienced Management: CHR's management team is considered experienced (4.1 years average tenure).
|Independent Vice Chairman||no data||€127.00k||0.0035% |
|Independent Chairman of the Board||1.92yrs||€217.00k||0.0019% |
|Independent Director||3.92yrs||€88.00k||0.0017% |
|Independent Director||10yrs||€129.00k||0.0023% |
|Independent Director||5.92yrs||€91.00k||0.0046% |
|Employee Representative Director||6.92yrs||€54.00k||0.00019% |
|Employee Representative Director||2.92yrs||€57.00k||0.000090% |
|Employee Representative Director||2.92yrs||€54.00k||0.00083% |
|Employee Representative Director||2.92yrs||€57.00k||0.000020% |
Experienced Board: CHR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Chr. Hansen Holding A/S's company bio, employee growth, exchange listings and data sources
- Name: Chr. Hansen Holding A/S
- Ticker: CHR
- Exchange: CPSE
- Founded: 1874
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: kr.87.504b
- Shares outstanding: 131.74m
- Website: https://www.chr-hansen.com
Number of Employees
- Chr. Hansen Holding A/S
- Bøge Allé 10-12
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHR||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Share Capital||DK||DKK||Jun 2010|
|51C||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jun 2010|
|0MR6||LSE (London Stock Exchange)||Yes||Share Capital||GB||DKK||Jun 2010|
|CRTS.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Jun 2010|
|CHRC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||DKK||Jun 2010|
|CHYH.Y||OTCPK (Pink Sheets LLC)||SPONSORED ADS||US||USD||May 2012|
Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North A ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/19 20:58|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.